Table 1.
Baseline clinical and laboratory characteristics of patients recruited to deuterium labeling studies.
| Trial ID | Age | Gender | Baseline | Binet Stage | IgVH | CD38 | FISH |
|---|---|---|---|---|---|---|---|
| (years) | Lymphocyte | (M/UM) | Expression | ||||
| (x109/L) | (%) | ||||||
| K1 | 66 | F | 7 | A | M | 7 | Normal |
| K2 | 55 | F | 200 | B | M | 0 | 13q- |
| K3 | 38 | F | 20 | A | M | 1 | Normal |
| K4 | 67 | F | 60 | A | M | 0 | Normal |
| K5 | 62 | M | 30 | A | M | 0 | Normal |
| K6 | 68 | M | 200 | B | M | 3 | 13q- |
| K7 | 65 | M | 90 | B | M | 0 | 13q- |
| K8 | 69 | M | 39 | B | M | 12 | Trisomy 12 |
| K9 | 54 | M | 100 | B | M | 0 | Normal |
| K10 | 53 | M | 20 | A | M | 51 | Trisomy 12 |
| Cal 001 | 71 | M | 222 | C | M | 7 | Normal |
| Cal 002 | 85 | M | 189 | C | M | 8 | 13q- |
Patients recruited to the CALiBRe study (n = 2) are identified by the prefix ‘Cal’.